April 7, 2008 |
The cholesterol drug did absolutely everything it was supposed to do -- except for demonstrably improving the health of the people who took it. That was the conclusion reached about the popular drug Vytorin in a study published online last week in the New England Journal of Medicine. The results were a disappointment to the millions of patients who take Vytorin and the thousands of doctors who prescribe it; a blow to its manufacturers, Merck & Co. and Schering-Plough Corp.
December 26, 2005 |
My husband takes HCTZ and Monopril for his hypertension, and Vytorin to lower his cholesterol. Since starting the drugs, he's had trouble with impotence. He refuses to see a urologist but takes an herb called horny goat weed instead. What effect could this herb have on his other medications? Clinical data to support the effectiveness of horny goat weed ( Epimedium) for erectile dysfunction or low libido are limited. What's more, products being sold as horny goat weed vary tremendously.
August 6, 2009 |
Merck & Co. and Schering-Plough Corp. said they would pay $41.5 million to settle lawsuits alleging they delayed unfavorable study results because the results would hurt sales. In January 2008 the drug makers, partners on two blockbuster cholesterol drugs, released long-awaited study data showing that Vytorin and Zetia were no more effective than an older, less-expensive cholesterol treatment aimed at reducing plaque buildup in arteries of people whose genes gave them sky-high cholesterol.
December 21, 2009 |
Q: Recently I heard a suggestion that niacin would be better and cheaper than Vytorin for lowering cholesterol. A: In a November study in the New England Journal of Medicine, niacin was compared with ezetimibe (Zetia), one part of the combination medicine Vytorin. All 200 patients took a statin cholesterol-lowering drug, but some took prescription niacin and others Zetia in addition to the statin. Niacin worked better than Zetia for cardiovascular health. We believe niacin should be used only under medical supervision.
June 9, 2011 |
All statins, a popular type of cholesterol-lowering drug, carry a low risk of muscle injury. But patients on the highest dose of the drug simvastatin, most commonly known as Zocor, seem to be at an elevated risk—so doctors should stop prescribing that dose for most people, the Food and Drug Administration has advised. That dose, 80 milligrams, should continue to be taken only by patients who have taken it for at least 12 months without muscle injury, the agency said Wednesday in a safety announcement . Everyone else should heed the FDA’s updated labels on simvastatin, and simvastatin-containing drugs such as Vytorin and Simcor.
March 3, 2008 |
Years of high-profile court battles over drugs such as Vioxx and Celebrex, along with billion-dollar settlements and jury verdicts, could soon be a thing of the past. The U.S. Supreme Court, in an 8-1 decision, ruled last month that patients injured by most medical devices can't sue their manufacturers. And this fall, a similar case could extend the same legal protection to the much larger pharmaceutical industry -- a frequent target of lawsuits. In last month's case, the high court backed a legal theory, supported by the Bush administration, that maintains that the Food and Drug Administration adequately regulates the drug and device industries and should not be second-guessed by courts.